Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use

The consistency of the progression-free survival benefit with Novartis’ Afinitor (everolimus) led FDA’s Oncologic Drugs Advisory Committee to support the drug’s approval for treatment of advanced pancreatic neuroendocrine tumors (PNET) despite questions about the statistical treatment of data in the pivotal study.